B-ly7 (CD103) / B-ly8 (CD22) dual combination is a direct immunofluorescence reagent used for detection and follow-up of B cell malignancies. The specificity of B-ly7 for diagnosis of HCL can be enhanced using double staining protocols with B cell markers such as CD22.